Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2998221 | 0.93 | NR1H4 (0.37) | PTGDR2PTGDRCNR1MAPTSLC6A3 | |
| SCHEMBL2992060 | 0.91 | FABP4 (0.34) | CNR1TP53MAPTERCC5FEN1 | |
| SCHEMBL2998826 | 0.85 | KDM4E (0.36) | TP53MAPT | |
| SCHEMBL2987937 | 0.85 | CNR1 (0.35) | CNR1MAPT | |
| SCHEMBL2999724 | 0.85 | NR1H4 (0.36) | PTGDR2PTGDRPTGER2CNR1MAPT | |
| SCHEMBL2992096 | 0.84 | CYP3A4 (0.41) | CNR1TP53MAPTCYP3A4CYP2C19 | |
| SCHEMBL2997041 | 0.80 | MAPK1 (0.44) | TP53MAPTCYP3A4TACR1 | |
| SCHEMBL2988625 | 0.80 | PTGDR (0.35) | PTGDR2PTGDRCNR1SLC6A3TACR1 | |
| SCHEMBL2994263 | 0.80 | ALOX5 (0.36) | TP53MAPT | |
| SCHEMBL2989195 | 0.79 | CNR1 (0.38) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781431-B2 | Thienopyrroles as antiviral agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2010-08-24 | — | — | US | disclosed |
| US-20090036443-A1 | Thienopyrroles as antiviral agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI (IT) | 2009-02-05 | — | — | US | disclosed |
| EP-1664059-B1 | THIENOPYRROLES AS ANTIVIRAL AGENTS | ANGELETTI P IST RICHERCHE BIO (IT) | 2007-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036443-A1 | Thienopyrroles as antiviral agents | ZC3HAV1, XDH, TPMT | PTGDR2 1883/4885PTGDR 981/4885PTGER2 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.